Actuate Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $5.4 million, a decrease from a loss of $6.0 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $17.7 million, compared to $20.8 million for the same period in 2024. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $2.2 million from $3.8 million year-over-year, primarily due to lower patient fees and costs associated with clinical trials. General and administrative expenses, however, increased to $3.3 million from $1.6 million, driven by higher personnel-related costs and consulting fees.
Actuate's total operating expenses for the third quarter were $5.5 million, slightly higher than the $5.4 million reported in the prior year. The company’s cash and cash equivalents as of September 30, 2025, stood at $16.9 million, a notable increase from $8.6 million at the end of 2024. This increase is largely due to successful financing activities, including a public offering that generated net proceeds of $15.6 million in September 2025 and a private placement that brought in $4.6 million in June 2025.
In terms of strategic developments, Actuate has made significant progress with its lead product candidate, elraglusib, which is currently in a Phase 2 clinical trial for metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial has shown promising results, meeting its primary endpoint of improved median overall survival compared to the control group. The company is also exploring additional indications for elraglusib, including pediatric cancers, and plans to advance its clinical program for Ewing sarcoma in 2026.
Operationally, Actuate has focused on expanding its clinical trials and enhancing its research capabilities. The company has increased its employee headcount to support these initiatives, although specific numbers were not disclosed. Actuate's management anticipates that ongoing and future clinical trials will require substantial capital, and they have expressed concerns about the company's ability to continue operations without additional funding. The company has indicated that its current cash reserves may not sustain operations beyond the second quarter of 2026, highlighting the need for further capital raises.
Looking ahead, Actuate Therapeutics remains committed to advancing elraglusib through clinical trials and seeking regulatory approvals. The company is actively engaging with the FDA regarding its Breakthrough Therapy Designation application and plans to request meetings to clarify the design of future clinical trials. However, the company acknowledges the inherent risks and uncertainties in drug development and the potential for significant operating losses as it continues to invest in its research and development efforts.
About ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing GSK-3 inhibitors, primarily elraglusib, for high-impact cancers like pancreatic ductal adenocarcinoma and pediatric malignancies. Its therapies aim to enhance immune response, inhibit tumor growth, and improve survival in difficult-to-treat cancers through innovative formulations and combination strategies, leveraging partnerships and regulatory incentives to accelerate development and approval.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.